Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2015-02-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2014-4332PMID 25642591PMCID PMC4399282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Streamlining variability in hospital charges for standard thyroidectomy: Developing a strategy to decrease waste.

  2014cited by this paper
• Cancer treatment and survivorship statistics, 2014

  2014cited by this paper
• Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer.

  2012cited by this paper
• Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy

  2011cited by this paper
• Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer

  2011cited by this paper
• Thyroid cancer survival in the United States: observational data from 1973 to 2005.

  2010cited by this paper
• Using the NCDB for cancer care improvement: An introduction to available quality assessment tools

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

  2009cited by this paper
• The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States

  2008cited by this paper
• Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope

  2007cited by this paper
• Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy

  2006cited by this paper
• Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.

  2006cited by this paper
• Quality of Life with Well-Differentiated Thyroid Cancer: Treatment Toxicities and Their Reduction

  2004cited by this paper
• Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients

  2002cited by this paper
• Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease.

  1996cited by this paper
• Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.

  1994cited by this paper
• Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

  1994cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper

• Comment on the ATA 2025 guidelines in adult DTC: is the pendulum swinging away from radioiodine or not?

  2026cites this paper
• Pharmacological Enhancement of Radionuclide Therapy Using Radiopharmaceutical-Drug Combinations in Oncology.

  2025cites this paper
• Prognostic Indicators and Comparative Treatment Outcomes in High-Risk Thyroid Cancer with Laryngotracheal Invasion

  2025cites this paper
• Comparative survival outcomes of lobectomy versus total thyroidectomy in T1 and T2 papillary thyroid cancer with more than five positive lymph nodes

  2025influential citation
• Multicenter analysis of radioactive iodine therapy outcomes after total thyroidectomy for T1-T2 stage papillary thyroid carcinoma with cervical lymph node metastasis in China

  2025cites this paper
• Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer

  2025cites this paper
• Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: a systematic review and meta-analysis

  2025influential citation
• Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review

  2025cites this paper
• From 2015 to 2025: how ATA guidelines reshape nuclear medicine practice in thyroid cancer

  2025cites this paper
• Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer

  2025influential citation
• Nomogram for survival prediction in metastatic differentiated thyroid cancer and survival comparison between systemic chemotherapy and local radiotherapy in high-risk patients

  2025cites this paper
• Research Progress on Integrative Traditional Chinese and Western Medicine Treatment for Differentiated Thyroid Cancer

  2025cites this paper
• The Evolving Role of Radioactive Iodine in Thyroid Cancer Diagnosis and Treatment.

  2025cites this paper
• The Impact of Radioactive Iodine on Outcomes Among Pediatric and Adolescent Thyroid Cancer Patients: A SEER Database Analysis

  2025cites this paper
• Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources

  2025cites this paper
• Evolving Paradigm in Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Historical Perspectives, Current Practices and Future Directions

  2025cites this paper
• Patient Perspectives Toward a Decision Aid for Radioactive Iodine Treatment for Intermediate Risk Thyroid Cancer.

  2025cites this paper
• Clinical Role of Pre-ablation Stimulated Thyroglobulin and Thyroid-Stimulating Hormone Ratio for Radioactive Iodine Treatment in Adults with Papillary Thyroid Cancer.

  2025cites this paper
• A Deep Learning Survival Model for Evaluating the Survival Prognosis of Papillary Thyroid Cancer: A Population-Based Cohort Study

  2025cites this paper
• Prevalence of endogenous normal thyroid function 3 years after hemithyroidectomy for differentiated thyroid cancer

  2025cites this paper
• 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

  2025cites this paper
• Radioactive iodine for differentiated thyroid carcinoma.

  2025cites this paper
• Second Primary Papillary Thyroid Carcinoma: Insights From Competing Risk Analysis and Post‐RAIT

  2025cites this paper
• Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect

  2024cites this paper
• The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma

  2024cites this paper
• Consider or not consider: the unsolved question on the use of radioactive iodine for differentiated thyroid cancer with low to intermediate risk of recurrence

  2024cites this paper
• A Comparative Analysis of Total Thyroidectomy and Lobectomy as Surgical Approaches in Patients Undergoing Thyroid Surgery

  2024cites this paper
• Continuing De-escalation Trends: Is Adjuvant Radioactive Iodine Administration Truly Needed for Papillary Thyroid Carcinoma with Limited Cervical Disease?

  2024cites this paper
• Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma

  2024cites this paper
• Differentiated Thyroid Cancer in Children and Adolescents: 12-year Experience in a Single Center

  2024cites this paper
• Predictors of distant metastatic recurrence in intermediate‐risk papillary thyroid carcinoma

  2024cites this paper
• Controversies in the management of intermediate-risk differentiated thyroid cancer.

  2024cites this paper
• Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma

  2024influential citation
• The Impact of Radioactive Iodine on Disease-Specific Survival in Low-to-Intermediate Risk N1b Papillary Thyroid Carcinoma

  2024cites this paper
• Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma

  2024cites this paper
• Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II

  2024cites this paper
• Efficacy of postoperative radioactive iodine therapy for patients with low and intermediate risk papillary thyroid carcinoma

  2024cites this paper
• Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment

  2024cites this paper
• Adjuvant Radioactive Iodine Ablation in Tall Cell Subtype Papillary Thyroid Cancer: A Systematic Review and Meta-analysis.

  2024cites this paper
• Theranostics of Thyroid Cancer.

  2024cites this paper
• Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer

  2024cites this paper
• Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.

  2024cites this paper
• Extent of surgery for unilateral papillary thyroid cancer with nonsuspicious contralateral nodules by ultrasound

  2024cites this paper
• Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System

  2024cites this paper
• Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

  2023cites this paper
• Impact factors of benefiting from initial 131I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response

  2023cites this paper
• Management of aggressive variants of papillary thyroid cancer

  2023cites this paper
• Impact of radioiodine therapy on recurrence and survival outcomes in intermediate‐risk papillary thyroid carcinoma —A systematic review and meta‐analysis

  2023cites this paper
• Rural-Urban Disparities in the Continuum of Thyroid Cancer Care: Analysis of 92,794 Cases

  2023cites this paper
• Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.

  2023cites this paper
• Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.

  2023cites this paper
• Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches.

  2023cites this paper
• Disparities in Initial Thyroid Cancer Care by Hospital Treatment Volume: Analysis of 52,599 Cases in California

  2023cites this paper
• Harnessing Immunity to Treat Advanced Thyroid Cancer

  2023cites this paper
• Current practice in intermediate risk differentiated thyroid cancer – a review

  2023cites this paper
• Pathogenesis of cancers derived from thyroid follicular cells

  2023cites this paper
• Comparison of Treatment and Prognosis Between Follicular Variant Papillary Thyroid Carcinoma and Classical Papillary Thyroid Carcinoma

  2023cites this paper
• Aspects Considered in Differentiated Thyroid Cancer for Radioiodine Therapy

  2023cites this paper
• Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma

  2023cites this paper
• Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

  2023cites this paper
• A comprehensive comparative assessment of eight risk stratification systems for thyroid nodules in the elderly population

  2023cites this paper
• Linear Association between Radioactive Iodine Dose and Second Primary Malignancy Risk in Thyroid Cancer.

  2023cites this paper
• Development and validation of nomograms for predicting survival in differentiated thyroid cancer patients with or without radioiodine therapy

  2023cites this paper
• Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.

  2023cites this paper
• The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study

  2023cites this paper
• A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer

  2023cites this paper
• Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels.

  2023cites this paper
• Recurrence-free survival and prognosis after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma

  2023cites this paper
• Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review

  2023cites this paper
• Tyrosinkinaseinhibitoren bei Patienten mit radiojodrefraktärem differenziertem Schilddrüsenkarzinom

  2023cites this paper
• SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective

  2022cites this paper
• UPDATED UNDERSTANDING OF THE MOLECULAR TARGETS OF RADIOIODINE IN DIFFERENTIATED THYROID CANCER.

  2022cites this paper
• An immediate postoperative response to therapy assessment can help avoid unnecessary RAI therapy

  2022cites this paper
• Radioiodine therapy in the different stages of differentiated thyroid cancer.

  2022cites this paper
• Strategies for Radioiodine Treatment: What’s New

  2022cites this paper
• Impact of Endocrinologist and Surgeon Density on Well-Differentiated Thyroid Cancer Survival

  2022cites this paper
• Radioactive iodine therapy: multiple faces of the same polyhedron

  2022cites this paper
• Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer

  2022cites this paper
• Proposed Risk Stratification and Patterns of Radioactive Iodine Therapy in Malignant Struma Ovarii

  2022cites this paper
• Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics

  2022cites this paper
• Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center

  2022influential citation
• Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma

  2022cites this paper
• Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence

  2022cites this paper
• Shared Decision Making for Radioiodine Therapy and the Actual Pattern of Care in Intermediate-Risk Differentiated Thyroid Carcinoma

  2022influential citation
• SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.

  2022cites this paper
• Prophylactic Central Neck Dissection for cN1b Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

  2022cites this paper
• Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis

  2022cites this paper
• Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration

  2022cites this paper
• Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.

  2022cites this paper
• Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.

  2022cites this paper
• Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy – A German position paper from Surgery and Nuclear Medicine

  2022cites this paper
• Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values.

  2022cites this paper
• Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients

  2021cites this paper
• Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience

  2021cites this paper
• Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications

  2021cites this paper
• Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.

  2021cites this paper
• Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

  2021cites this paper
• Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?

  2021influential citation
• Influence of Levothyroxine with Recombinant Human TSH on Urine Iodine Excretion Before Radioactive Iodine Administration.

  2021cites this paper
• Central Compartment Nodal Disease in Small Papillary Thyroid Carcinomas in Singapore

  2021cites this paper